Appili Therapeutics APLIF Stock
Appili Therapeutics Price Chart
Appili Therapeutics APLIF Financial and Trading Overview
| Appili Therapeutics stock price | 0.01 USD |
| Previous Close | 0.01 USD |
| Open | 0.01 USD |
| Bid | 0.01 USD x 2000000 |
| Ask | 0.01 USD x 4140000 |
| Day's Range | 0.01 - 0.01 USD |
| 52 Week Range | 0.009 - 0.03 USD |
| Volume | 5.7K USD |
| Avg. Volume | 23.59K USD |
| Market Cap | 1.54M USD |
| Beta (5Y Monthly) | -0.3 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
APLIF Valuation Measures
| Enterprise Value | 13.77M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.24 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.4664 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 66.745 |
| Enterprise Value/EBITDA | -2.235 |
Trading Information
Appili Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.3 |
| 52-Week Change | -14.28% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.03 USD |
| 52 Week Low | 0.009 USD |
| 50-Day Moving Average | 0.01 USD |
| 200-Day Moving Average | 0.02 USD |
APLIF Share Statistics
| Avg. Volume (3 month) | 23.59K USD |
| Avg. Daily Volume (10-Days) | 1.27K USD |
| Shares Outstanding | 128.37M |
| Float | 114.37M |
| Short Ratio | N/A |
| % Held by Insiders | 0.056% |
| % Held by Institutions | 10.84% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | March 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -623.85% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -291.97% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 206.31K USD |
| Revenue Per Share (ttm) | 0.002 USD |
| Quarterly Revenue Growth (yoy) | 6.09% |
| Gross Profit (ttm) | 206.31K USD |
| EBITDA | -6160052 USD |
| Net Income Avi to Common (ttm) | -2963623 USD |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 212.75K USD |
| Total Cash Per Share (mrq) | 0.002 USD |
| Total Debt (mrq) | 12.46M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.033 |
| Book Value Per Share (mrq) | -0.09271334 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -11332 USD |
| Levered Free Cash Flow (ttm) | -3018715 USD |
Profile of Appili Therapeutics
| Country | United States |
| State | NS |
| City | Halifax |
| Address | 1344 Summer Street |
| ZIP | B3H 0A8 |
| Phone | 902 442 4655 |
| Website | https://appilitherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 7 |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Q&A For Appili Therapeutics Stock
What is a current APLIF stock price?
Appili Therapeutics APLIF stock price today per share is 0.01 USD.
How to purchase Appili Therapeutics stock?
You can buy APLIF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Appili Therapeutics?
The stock symbol or ticker of Appili Therapeutics is APLIF.
Which industry does the Appili Therapeutics company belong to?
The Appili Therapeutics industry is Biotechnology.
How many shares does Appili Therapeutics have in circulation?
The max supply of Appili Therapeutics shares is 128.37M.
What is Appili Therapeutics Price to Earnings Ratio (PE Ratio)?
Appili Therapeutics PE Ratio is now.
What was Appili Therapeutics earnings per share over the trailing 12 months (TTM)?
Appili Therapeutics EPS is -0.01 USD over the trailing 12 months.
Which sector does the Appili Therapeutics company belong to?
The Appili Therapeutics sector is Healthcare.